With homage to "Rent" …
Two million, six hundred twenty-eight thousand minutes
Two million, six hundred twenty-eight thousand moments so dear
Two million, six hundred twenty-eight thousand minutes
How do you measure, measure five years?
In weddings, in anniversaries
In seasons, in birthdays
In graduations, in promotions
In vacations, in holidays
Two million, six hundred twenty-eight thousand minutes
How do you measure five years of life?
Now, that’s a very real question for people living with advanced heart failure. Recently released data from the MOMENTUM 3 study of more than 1,000 patients show, for the first time, those given the opportunity to be considered for the HeartMate 3 left ventricular assist device (LVAD, also known as a heart pump), could have five years — and beyond — to measure in memories.
Prior data1 showed that, without either a heart transplant or pump, they would have limited therapy options or would require living with inotropic medication to help strengthen their heart function, limiting their median survival to less than a year.
Millions Can Benefit
More than 6.2 million Americans have heart failure.2 Diagnoses are projected to double3 by 2030. Only about 3,600 will receive a new heart.
"The problem is the number of patients who need either transplant or an LVAD is so utterly off the charts, the number of transplants is hopelessly small compared to the number of people who need circulatory support," said Kevin Bourque, who has worked on the design of the HeartMate line of pumps since the beginning.
More than 20,000 people have benefitted from HeartMate 3, the only commercially approved heart pump with Full MagLev technology, which allows the device’s rotor to be “suspended” by magnetic forces.
But that's just scratching the surface for those 6.2 million.
"Thousands of people with advanced heart failure die every year because they do not receive a heart pump, largely because their physicians are not aware of the option or its full benefits," said Keith Boettiger, vice president of Abbott's heart failure business. "There are too many patients who aren't provided the opportunity to be evaluated for a heart pump. With broader awareness and improved access to a heart pump, we can give these patients a chance at a longer, fuller life."
Zuleyma is one of the 20,000 plus HeartMate 3 recipients experiencing the benefits of more time to be the mother her children need.
The MOMENTUM 3 data show this technology could help so many more.
If you were faced with the all-too-real prospect of just one more year of life — as so many living with and dying from advanced heart failure are making sense of right now — what would you do with five more years?
Two million, six hundred twenty-eight thousand minutes
Two million, six hundred twenty-eight thousand moments so dear
Two million, six hundred twenty-eight thousand minutes
How do you measure, measure five years?
In fireworks, in presents
In games, in plays
In parades, in events
In all the months, and all the days
Two million, six hundred twenty-eight thousand minutes
How do you measure five years of life?
References
1Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Taimoor Hashim, MD; Kumar Sanam, MD; Marina Revilla-Martinez, MD; Charity J. Morgan, PhD; Jose A. Tallaj, MD; Salpy V. Pamboukian, MD, MSPH; Renzo Y. Loyaga-Rendon, MD, PhD; James F. George, PhD; Deepak Acharya, MD, MSPH. Circ Heart Fail. 2015;8:880-886. DOI: 10.1161/CIRCHEARTFAILURE.114.001778.
2Centers for Disease Control and Prevention. Facts About Heart Failure in the United States. Heart Failure | cdc.gov. Accessed Dec. 30, 2021.
3Circ Heart Fail. 2015;8:880-886. DOI: 10.1161/CIRCHEARTFAILURE.114.001778.
IMPORTANT SAFETY INFORMATION
HEARTMATE 3
INDICATIONS, SAFETY & WARNINGS
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
HeartMate 3™ Left Ventricular Assist System
Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.
Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.
HeartMate 3 Coring Tool
Indications: For the HeartMate 3 Left Ventricular Assist System (LVAS) Indications for Use, please refer to the HeartMate 3 LVAS Instructions for Use. The HeartMate 3™ Coring Tool is intended for use with the HeartMate 3 LVAS. The HeartMate 3 Coring Tool provides a means to resect a plug of myocardium from the left ventricle, which allows for HeartMate 3 inflow cannula insertion.
Contraindications: The use of the HeartMate 3 Coring Tool is contraindicated in patients who are contraindicated for HeartMate 3 Left Ventricular Assist System (LVAS) therapy.
Adverse Events: The following adverse events may be associated with the use of the HeartMate 3 Coring Tool. Adverse events are listed in anticipated decreasing order of frequency, except for death, which appears first as it is a non-reversible complication: death, bleeding (perioperative or late), local infection, local ischemia, cardiac arrhythmia, stroke, peripheral thromboembolic event, neurologic dysfunction, hemolysis, sepsis.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
FOLLOW ABBOTT